Treatment of short bowel syndrome patients with colon-in-continuity
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method of treating a patient having short bowel syndrome with at least 25% colon-in-continuity with remnant small intestine and who receives an amount of parenteral nutrition each week, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient.
2. The method as defined in claim 1 , wherein said patient has at least 30% colon-in-continuity with remnant small intestine.
3. The method as defined in claim 2 , wherein said patient has at least 35% colon-in-continuity with remnant small intestine.
4. The method as defined in claim 3 , wherein said patient has at least 40% colon-in-continuity with remnant small intestine.
5. The method as defined in claim 4 , wherein said patient has at least 45% colon-in-continuity with remnant small intestine.
6. The method as defined in claim 5 , wherein said patient has at least 50% colon-in-continuity with remnant small intestine.
7. The method as defined in claim 6 , wherein said patient has at least 60% colon-in-continuity with remnant small intestine.
8. The method as defined in claim 7 , wherein said patient has at least 70% colon-in-continuity with remnant small intestine.
9. The method as defined in claim 8 , wherein said patient has at least 80% colon-in-continuity with remnant small intestine.
10. The method as defined in claim 9 , wherein said patient has at least 90% colon-in-continuity with remnant small intestine.
11. The method as defined in claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
12. A method of treating a patient having short bowel syndrome with at least 25% colon-in-continuity with remnant small intestine and who receives parenteral nutrition each week, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient.
13. The method as defined in claim 12 , wherein said patient has at least 30% colon-in-continuity with remnant small intestine.
14. The method as defined in claim 13 , wherein said patient has at least 35% colon-in-continuity with remnant small intestine.
15. The method as defined in claim 14 , wherein said patient has at least 40% colon-in-continuity with remnant small intestine.
16. The method as defined in claim 15 , wherein said patient has at least 45% colon-in-continuity with remnant small intestine.
17. The method as defined in claim 16 , wherein said patient has at least 50% colon-in-continuity with remnant small intestine.
18. The method as defined in claim 17 , wherein said patient has at least 60% colon-in-continuity with remnant small intestine.
19. The method as defined in claim 18 , wherein said patient has at least 70% colon-in-continuity with remnant small intestine.
20. The method as defined in claim 19 , wherein said patient has at least 80% colon-in-continuity with remnant small intestine.
21. The method as defined in claim 20 , wherein said patient has at least 90% colon-in-continuity with remnant small intestine.
22. The method as defined in claim 1 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.
23. The method as defined in claim 12 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.
24. The method as defined in claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration.
25. The method as defined in claim 1 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
26. The method as defined in claim 12 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
27. The method as defined in claim 1 , wherein said patient is an adult.
28. The method as defined in claim 12 , wherein said patient is an adult.